ABCC2 c.-24 C>T single-nucleotide polymorphism was associated with the pharmacokinetic variability of deferasirox in Chinese subjects

  • Kangna Cao
  • Guanghui Ren
  • Chengcan Lu
  • Yao Wang
  • Yanan Tan
  • Jing Zhou
  • Yongjie Zhang
  • Yang Lu
  • Ning Li
  • Xijing ChenEmail author
  • Di ZhaoEmail author



Our aim was to evaluate the influence of genetic polymorphisms involved in the metabolism and transportation of deferasirox on deferasirox pharmacokinetics in the Chinese population.


Thirty-eight healthy Chinese subjects were administered with a single dose of 20 mg kg−1 deferasirox. Allelic discriminations for eight single-nucleotide polymorphisms (SNPs) in UDP-glucuronosyltransferase 1A1, 1A3 (UGT1A1, UGT1A3), multidrug resistance protein 2 (MRP2, ABCC2), and breast cancer resistance protein (BCRP, ABCG2) were performed. The concentrations of deferasirox in the plasma were determined by UPLC-MS/MS.


Subjects carrying ABCC2 c.-24 T allele had a 65% higher clearance (CL/F) and 42% lower area under the concentration–time curve from 0 to 72 h (AUC0-72h) as compared with non-carriers (P = 0.008, P = 0.011, respectively). ABCC2 c.-24 T was also associated with 59% shorter half-life (T1/2) and 17% shorter mean residence time (MRT) (P = 0.030, P = 0.014, respectively). ABCC2 1249A was associated with a marginal increase in deferasirox Cmax (P = 0.07). Genetic polymorphisms of UGT1A1, UGT1A3, and ABCG2 did not significantly influence the pharmacokinetics of deferasirox. Subjects with UGT1A1 211GG-(-1352)CC-(-3156)GG haplotype had higher AUC0-72h than others. Since only two subjects were recruited in the GG-CC-GG group, further confirmative studies were warranted.


ABCC2 c.-24 C>T was associated with the pharmacokinetic variability of deferasirox in Chinese subjects. This study revealed an important role of MRP2 in the pharmacokinetics of deferasirox and drew attention to drug combination with MRP2 inhibitors like cyclosporine and methotrexate in deferasirox therapy.


Deferasirox MRP2 Single-nucleotide polymorphism Pharmacogenetics Pharmacokinetics 


Contributions of authors statement

Di Zhao and Xijing Chen concepted, designed, and supervised the study. Kangna Cao, Guanghui Ren, Chengcan Lu, Yao Wang, Jing Zhou, and Yanan Tan performed the research. Kangna Cao and Di Zhao analyzed and interpreted the data, provided statistical analysis, had full access to all of the data in the study, and are responsible for the integrity of the data and the accuracy of the data analysis. Kangna Cao drafted the manuscript. Di Zhao, Yongjie Zhang, Yang Lu, and Ning Li critically revised the manuscript for important intellectual content.

Funding information

This study was supported by “Double First-Class” Initiative Innovation Team Project of China Pharmaceutical University (Team number CPU2018GY29) and the Fundamental Research Funds for the Central Universities (2632018PT02).

Compliance with ethical standards

All subjects provided verbal and written informed consent. This study was performed in accordance with the guidelines of the Declaration of Helsinki and was approved by the relevant institutional review board of the Lilairuide Clinic (Nanjing, China).

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

228_2019_2775_MOESM1_ESM.docx (26 kb)
ESM 1 (DOCX 26 kb)


  1. 1.
    Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, Ghilardi R, Origa R, Piga A, Romeo MA, Zhao H, Cnaan A (2005) Survival and complications in thalassemia. Ann N Y Acad Sci 1054:40–47. CrossRefPubMedGoogle Scholar
  2. 2.
    Borgna-Pignatti C, Vergine G, Lombardo T, Cappellini MD, Cianciulli P, Maggio A, Renda D, Lai ME, Mandas A, Forni G, Piga A, Bisconte MG (2004) Hepatocellular carcinoma in the thalassaemia syndromes. Br J Haematol 124(1):114–117CrossRefPubMedGoogle Scholar
  3. 3.
    Bergeron RJ, Wiegand J, Bharti N, McManis JS, Singh S (2011) Desferrithiocin analogue iron chelators: iron clearing efficiency, tissue distribution, and renal toxicity. Biometals 24(2):239–258. CrossRefPubMedGoogle Scholar
  4. 4.
    Chaudhary P, Pullarkat V (2013) Deferasirox: appraisal of safety and efficacy in long-term therapy. Journal of blood medicine 4:101–110. CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Lai YR, Liu RR, Li CF, Huang SL, Li Q, Habr D, Martin N, Shen ZX (2013) Efficacy of deferasirox for the treatment of iron overload in Chinese thalassaemia major patients: results from a prospective, open-label, multicentre clinical trial. Transfus Med 23(6):389–396. CrossRefPubMedGoogle Scholar
  6. 6.
    Naderi M, Sadeghi-Bojd S, Valeshabad AK, Jahantigh A, Alizadeh S, Dorgalaleh A, Tabibian S, Bamedi T (2013) A prospective study of tubular dysfunction in pediatric patients with beta thalassemia major receiving deferasirox. Pediatr Hematol Oncol 30(8):748–754. CrossRefPubMedGoogle Scholar
  7. 7.
    Chirnomas D, Smith AL, Braunstein J, Finkelstein Y, Pereira L, Bergmann AK, Grant FD, Paley C, Shannon M, Neufeld EJ (2009) Deferasirox pharmacokinetics in patients with adequate versus inadequate response. Blood 114(19):4009–4013. CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Cappellini M, Taher A (2009) Deferasirox (Exjade®) for the treatment of iron overload. Acta Haematol 122(2-3):165–173CrossRefPubMedGoogle Scholar
  9. 9.
    Osborne V, Davies M, Layton D, Shakir SAW (2018) Utilisation and safety of deferasirox: results from an observational cohort study in England. Drug Saf 41(3):267–275. CrossRefPubMedGoogle Scholar
  10. 10.
    Fucile C, Mattioli F, Marini V, Gregori M, Sonzogni A, Martelli A, Maximova N (2018) What is known about deferasirox chelation therapy in pediatric HSCT recipients: two case reports of metabolic acidosis. Ther Clin Risk Manag 14:1649–1655. CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Papadopoulos N, Vasiliki A, Aloizos G, Tapinis P, Kikilas A (2010) Hyperchloremic metabolic acidosis due to deferasirox in a patient with beta thalassemia major. Ann Pharmacother 44(1):219–221CrossRefPubMedGoogle Scholar
  12. 12.
    Galanello R, Piga A, Cappellini MD, Forni GL, Zappu A, Origa R, Dutreix C, Belleli R, Ford JM, Riviere GJ, Balez S, Alberti D, Sechaud R (2008) Effect of food, type of food, and time of food intake on deferasirox bioavailability: recommendations for an optimal deferasirox administration regimen. J Clin Pharmacol 48(4):428–435. CrossRefPubMedGoogle Scholar
  13. 13.
    Sechaud R, Dutreix C, Balez S, Pommier F, Dumortier T, Morisson S, Brun E (2008) Relative bioavailability of deferasirox tablets administered without dispersion and dispersed in various drinks. Int J Clin Pharmacol Ther 46(2):102–108. CrossRefPubMedGoogle Scholar
  14. 14.
    Nisbet-Brown E, Olivieri NF, Giardina PJ, Grady RW, Neufeld EJ, Séchaud R, Krebs-Brown AJ, Anderson JR, Alberti D, Sizer KC (2003) Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 361(9369):1597–1602CrossRefPubMedGoogle Scholar
  15. 15.
    Allegra S, De Francia S, Cusato J, Pirro E, Massano D, Piga A, D’Avolio A (2016) Deferasirox pharmacokinetic and toxicity correlation in beta-thalassaemia major treatment. J Pharm Pharmacol 68(11):1417–1421. CrossRefPubMedGoogle Scholar
  16. 16.
    Miyazawa K, Ohyashiki K, Urabe A, Hata T, Nakao S, Ozawa K, Ishikawa T, Kato J, Tatsumi Y, Mori H, Kondo M, Taniguchi J, Tanii H, Rojkjaer L, Omine M (2008) A safety, pharmacokinetic and pharmacodynamic investigation of deferasirox (Exjade, ICL670) in patients with transfusion-dependent anemias and iron-overload: a phase I study in Japan. Int J Hematol 88(1):73–81. CrossRefPubMedGoogle Scholar
  17. 17.
    Galanello R, Piga A, Alberti D, Rouan MC, Bigler H, Sechaud R (2003) Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia. J Clin Pharmacol 43(6):565–572CrossRefPubMedGoogle Scholar
  18. 18.
    Waldmeier F, Bruin GJ, Glaenzel U, Hazell K, Sechaud R, Warrington S, Porter JB (2010) Pharmacokinetics, metabolism, and disposition of deferasirox in beta-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state. Drug metabolism and disposition: the biological fate of chemicals 38(5):808–816. CrossRefGoogle Scholar
  19. 19.
    Exjade® (deferasirox). Prescribing information. NOVARTIS. Accessed 01 June, 2019.
  20. 20.
    Bruin GJ, Faller T, Wiegand H, Schweitzer A, Nick H, Schneider J, Boernsen KO, Waldmeier F (2008) Pharmacokinetics, distribution, metabolism, and excretion of deferasirox and its iron complex in rats. Drug Metab Dispos 36(12):2523–2538. CrossRefPubMedGoogle Scholar
  21. 21.
    Lee JW, Kang HJ, Choi JY, Kim NH, Jang MK, Yeo CW, Lee SS, Kim H, Park JD, Park KD, Shin HY, Shin JG, Ahn HS (2013) Pharmacogenetic study of deferasirox, an iron chelating agent. PLoS One 8(5):e64114. CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Cusato J, Allegra S, Massano D, De Francia S, Piga A, D’Avolio A (2015) Influence of single-nucleotide polymorphisms on deferasirox C trough levels and effectiveness. Pharmacogenomics J 15(3):263–271. CrossRefPubMedGoogle Scholar
  23. 23.
    Mattioli F, Puntoni M, Marini V, Fucile C, Milano G, Robbiano L, Perrotta S, Pinto V, Martelli A, Forni GL (2015) Determination of deferasirox plasma concentrations: do gender, physical and genetic differences affect chelation efficacy? Eur J Haematol 94(4):310–317. CrossRefPubMedGoogle Scholar
  24. 24.
    Allegra S, Cusato J, De Francia S, Massano D, Piga A, D’Avolio A (2016) Deferasirox AUC efficacy cutoff and role of pharmacogenetics. Eur J Clin Pharmacol 72(9):1155–1157. CrossRefPubMedGoogle Scholar
  25. 25.
    Cusato J, Allegra S, De Francia S, Massano D, Piga A, D’Avolio A (2016) Role of pharmacogenetics on deferasirox AUC and efficacy. Pharmacogenomics 17(6):561–572. CrossRefPubMedGoogle Scholar
  26. 26.
    Allegra S, Cusato J, De Francia S, Arduino A, Longo F, Pirro E, Massano D, De Nicolo A, Piga A, D’Avolio A (2017) Role of CYP24A1, VDR and GC gene polymorphisms on deferasirox pharmacokinetics and clinical outcomes. Pharmacogenomics J 18:506–515. CrossRefPubMedGoogle Scholar
  27. 27.
    Allegra S, De Francia S, Cusato J, Arduino A, Massano D, Longo F, Piga A, D’Avolio A (2017) Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients. Pharmacogenomics 18(6):539–554. CrossRefPubMedGoogle Scholar
  28. 28.
    Allegra S, Cusato J, De Francia S, Longo F, Pirro E, Massano D, Avataneo V, De Nicolo A, Piga A, D’Avolio A (2018) Role of CYP1A1, ABCG2, CYP24A1 and VDR gene polymorphisms on the evaluation of cardiac iron overload in thalassaemia patients. Pharmacogenet Genomics 28(9):199–206. CrossRefPubMedGoogle Scholar
  29. 29.
    Allegra S, Cusato J, De Francia S, Longo F, Pirro E, Massano D, Piga A, D’Avolio A (2018) Effect of pharmacogenetic markers of vitamin D pathway on deferasirox pharmacokinetics in children. Pharmacogenet Genomics 28(1):17–22. CrossRefPubMedGoogle Scholar
  30. 30.
    Yan P, Qiao X, Wu H, Yin F, Zhang J, Ji Y, Wei S, Lai J (2016) An association study between genetic polymorphisms in functional regions of five genes and the risk of schizophrenia. J Mol Neurosci : MN 59(3):366–375. CrossRefPubMedGoogle Scholar
  31. 31.
    Li T, Cui Z, Wang Y, Yang W, Li D, Song Q, Sun L, Ding L (2018) A simple LC-MS/MS method for determination of deferasirox in human plasma: troubleshooting of interference from ferric ion in method development and its application. J Pharm Biomed Anal 151:145–150. CrossRefPubMedGoogle Scholar
  32. 32.
    Glatard A, Guidi M, Dobrinas M, Cornuz J, Csajka C, Eap CB (2019) Influence of body weight and UGT2B7 polymorphism on varenicline exposure in a cohort of smokers from the general population. Eur J Clin Pharmacol 75:939–949. CrossRefPubMedGoogle Scholar
  33. 33.
    Wang D, Chen X, Li Z (2019) Cyclosporin population pharmacokinetics in pediatric refractory nephrotic syndrome based on real-world studies: effects of body weight and spirolactone administration. Experimental and therapeutic medicine 17(4):3015–3020. CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Zhang Y, Zhao T, Li W, Vore M (2010) The 5′-untranslated region of multidrug resistance associated protein 2 (MRP2; ABCC2) regulates downstream open reading frame expression through translational regulation. Mol Pharmacol 77(2):237–246. CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Haenisch S, Zimmermann U, Dazert E, Wruck CJ, Dazert P, Siegmund W, Kroemer HK, Warzok RW, Cascorbi I (2007) Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex. The pharmacogenomics journal 7(1):56–65. CrossRefPubMedGoogle Scholar
  36. 36.
    Hirouchi M, Suzuki H, Itoda M, Ozawa S, Sawada J, Ieiri I, Ohtsubo K, Sugiyama Y (2004) Characterization of the cellular localization, expression level, and function of SNP variants of MRP2/ABCC2. Pharm Res 21(5):742–748CrossRefPubMedGoogle Scholar
  37. 37.
    Meyer zu Schwabedissen HE, Jedlitschky G, Gratz M, Haenisch S, Linnemann K, Fusch C, Cascorbi I, Kroemer HK (2005) Variable expression of MRP2 (ABCC2) in human placenta: influence of gestational age and cellular differentiation. Drug metabolism and disposition: the biological fate of chemicals 33 (7): 896-904 DOI CrossRefPubMedGoogle Scholar
  38. 38.
    van Gelder T, Klupp J, Barten MJ, Christians U, Morris RE (2001) Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit 23(2):119–128CrossRefPubMedGoogle Scholar
  39. 39.
    Bozina N, Lalic Z, Nad-Skegro S, Boric-Bilusic A, Bozina T, Kastelan Z, Trkulja V (2017) Steady-state pharmacokinetics of mycophenolic acid in renal transplant patients: exploratory analysis of the effects of cyclosporine, recipients’ and donors’ ABCC2 gene variants, and their interactions. Eur J Clin Pharmacol 73(9):1129–1140. CrossRefPubMedGoogle Scholar
  40. 40.
    Jaekel N, Lieder K, Albrecht S, Leismann O, Hubert K, Bug G, Kroger N, Platzbecker U, Stadler M, de Haas K, Altamura S, Muckenthaler MU, Niederwieser D, Al-Ali HK (2016) Efficacy and safety of deferasirox in non-thalassemic patients with elevated ferritin levels after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 51(1):89–95. CrossRefPubMedGoogle Scholar
  41. 41.
    Jomen W, Kuroda H, Yamada M, Matsuno T, Sato M, Abe T, Sakurai T, Fujii S, Maeda M, Fujita M, Nagashima K, Iyama S, Miyanishi K, Kobune M, Kato J (2013) [Hematologic improvement with deferasirox following tandem antithymocyte globulin treatment in a transfusion-dependent patient with severe aplastic anemia]. [Rinsho ketsueki]. The Japanese journal of clinical hematology 54(11):2047–2052PubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Clinical Pharmacokinetics LaboratoryChina Pharmaceutical UniversityNanjingChina
  2. 2.National Experimental Teaching Demonstration Center of PharmacyChina Pharmaceutical UniversityNanjingChina

Personalised recommendations